X

Due to the lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at http://www.usa.gov.
NIH Guide: NOVEL TECHNOLOGIES FOR EVALUATION OF MOLECULAR ALTERATIONS INTISSUE - ADDENDUM

NOVEL TECHNOLOGIES FOR EVALUATION OF MOLECULAR ALTERATIONS INTISSUE - ADDENDUM

 

NIH GUIDE, Volume 26, Number 24, July 25, 1997

 

P.T.





Keywords:

 

National Cancer Institute

National Institute on Deafness and Other Communication Disorders

 

Letter of Intent Receipt Date:  September 15, 1997

Application Receipt Date:  November 13, 1997

 

PURPOSE

 

REMINDER OF NOVEMBER 13, 1997 RECEIPT DATE AND NOTICE OF CHANGE OF

ADDRESS FOR INQUIRIES.

 

The purpose of this notice is to invite applications proposing the

development of novel technologies to facilitate the generation of a

comprehensive molecular profile of human tissues for the second

receipt date of RFA CA-97-011.  This initiative is intended to

support the development of efficient, cost effective, sensitive

technologies that permit the simultaneous, rapid evaluation of the

spectrum of molecular alterations in tissue specimens and,

ultimately, in single cells. This RFA is sponsored by The Technology

Development Branch of the Cancer Diagnosis Program, Division of

Cancer Treatment, Diagnosis, and Centers, National Cancer Institute

and the Division of Human Communication of the National Institute on

Deafness and Other Communication Disorders.  For a complete

discussion of RFA 97-011, refer to the NIH Guide, Volume 26, number

2, January 17, 1997. This notice also provides updated information

concerning letter of intent receipt date and  new address information

for inquiries.  Approximately $1.5 million from NCI and $150,000 from

NIDCD are available and it is anticipated that six to eight

applications will be funded following review.

 

INQUIRIES

 

Inquiries concerning the RFA CA-97-011 are encouraged.  Please note

the change of address, phone and fax number for Dr. Jacobson given

below.  Letters of intent are not mandatory but are strongly

encouraged.

 

James Jacobson, Ph.D.

Division of Cancer Treatment, Diagnosis and Centers

National Cancer Institute

6130 Executive Blvd, Room 700, MSC 7388

Bethesda, MD 20892-7388

Telephone:  301 402 4185

FAX:  301 402 7819

Email:  jj37d@nih.gov

 

.


Return to 1997 Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.